EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AKT2 Exon 3 Variants and Their Prevalence in Prostate Cancer Patients: Insights from a Jordanian Clinical Cohort

Nuseibah Rahahlah, Zina Al-Alami iD, Mohammed S Alorjani iD, Asmaa Al-Smadi iD, Sewar Obeidat iD, Raed Otoom, Raed M Al-Zoubi iD, Samir Al Bashir, Mazhar Salim Al Zoubi iD

International Journal of Molecular Sciences · 09.05.2026 · 27 (10) · 4228

DOI: 10.3390/ijms27104228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2026. Verfasst von Nuseibah Rahahlah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, P.O. Box 115, Amman 19111, Jordan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Proto-Oncogene Proteins c-akt, Exons, Adenocarcinoma. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Ahlyyia ammanu university.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The AKT2 gene, located on chromosome 19, encodes a protein involved in key cellular processes like metabolism, proliferation, and survival. Abnormalities in the PI3K/AKT pathway, including AKT2, contribute to tumor progression. AKT2 promotes cell survival, growth, and resistance to therapy. Overexpression or hyperactivation of AKT2 is linked to prostate cancer (PC) development, making it a potential therapeutic target. This study aimed to investigate the frequency and distribution of AKT2 variants in a cohort of Jordanian men diagnosed with PC and to evaluate the relationship between these genetic variations and clinicopathological parameters, including age, tumor stage, PSA levels, and Gleason score. Formalin-fixed paraffin-embedded (FFPE) tissue samples (n = 123) were collected from Jordanian patients diagnosed with prostate adenocarcinoma. The collected samples underwent DNA extraction, followed by PCR amplification. Subsequently, exon 3 of AKT2 was sequenced. The prevalence of AKT2 mutations was 5.7% in the population studied. Six mutations were identified: two missense mutations (Pro51Ser and Gly33Ser), two synonymous, one splice acceptor, and one intron variant. The variants were not significantly correlated with clinical parameters; however, the prevalence of the AKT2 mutations suggests potential relevance to PC pathogenesis. The prevalence of AKT2 mutations in the current cohort suggested a potential role of AKT2 in PC pathogenesis in the Jordanian population. Further genetic studies covering the whole AKT2 gene and the downstream pathway are required for a better understanding of PC genetics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsProto-Oncogene Proteins c-aktExonsAdenocarcinomaHumansMaleJordanAgedMiddle AgedCohort StudiesPrevalenceMutationAged, 80 and over

Stichwörter der Autor:innen

AKT2adenocarcinomagood health and wellbeingkinasemutationsprostate cancer

Substanzen

Proto-Oncogene Proteins c-aktAKT2 protein, human

Autor:innen und Institutionen

  • Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, P.O. Box 115, Amman 19111, Jordan.
  • Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan.
  • Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid 21163, Jordan.
  • Surgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha P.O. Box 3050, Qatar.
  • Department of Biomedical Sciences, QU-Health, College of Health Sciences, Qatar University, Doha 2713, Qatar.
  • Department of Chemistry, Jordan University of Science and Technology, P.O. Box 3030, Irbid 22110, Jordan.

ORCID-Profile: Zina Al-Alami, Mohammed S Alorjani, Asmaa Al-Smadi, Sewar Obeidat, Raed M Al-Zoubi, Mazhar Salim Al Zoubi

Förderung

  • Al-Ahlyyia ammanu university

Zitieren

APA

Rahahlah, N., Al-Alami, Z., Alorjani, M. S., Al-Smadi, A., Obeidat, S., Otoom, R., Al-Zoubi, R. M., Al Bashir, S., & Al Zoubi, M. S. (2026). AKT2 Exon 3 Variants and Their Prevalence in Prostate Cancer Patients: Insights from a Jordanian Clinical Cohort. International Journal of Molecular Sciences, 27(10), 4228. https://doi.org/10.3390/ijms27104228

Vancouver

Rahahlah N, Al-Alami Z, Alorjani MS, Al-Smadi A, Obeidat S, Otoom R, et al. AKT2 Exon 3 Variants and Their Prevalence in Prostate Cancer Patients: Insights from a Jordanian Clinical Cohort. International Journal of Molecular Sciences. 2026;27(10):4228. doi:10.3390/ijms27104228

BibTeX
@article{Rahahlah2026,
  author = {Rahahlah, Nuseibah and Al-Alami, Zina and Alorjani, Mohammed S and Al-Smadi, Asmaa and Obeidat, Sewar and Otoom, Raed and Al-Zoubi, Raed M and Al Bashir, Samir and Al Zoubi, Mazhar Salim},
  title = {AKT2 Exon 3 Variants and Their Prevalence in Prostate Cancer Patients: Insights from a Jordanian Clinical Cohort},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4228},
  doi = {10.3390/ijms27104228}
}
Kostenlos starten →